Lutz Lingnau Sells 10,000 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
Nektar Therapeutics (NASDAQ:NKTR) Director Lutz Lingnau sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $34.63, for a total transaction of $346,300.00. Following the transaction, the director now directly owns 33,200 shares in the company, valued at $1,149,716. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Nektar Therapeutics stock opened at $33.53 on Friday. The company has a market cap of $6.08 billion, a price-to-earnings ratio of 8.87 and a beta of 2.75. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. The firm’s 50 day moving average is $34.01. Nektar Therapeutics has a 1 year low of $29.22 and a 1 year high of $69.76.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.03. The company had revenue of $28.22 million for the quarter, compared to analyst estimates of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same period in the previous year, the firm posted ($0.60) EPS. As a group, equities research analysts predict that Nektar Therapeutics will post -3.14 EPS for the current year.
A number of equities analysts recently commented on the stock. Mizuho reaffirmed a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a research report on Friday, May 24th. Svb Leerink began coverage on shares of Nektar Therapeutics in a report on Friday, March 15th. They issued a “mkt perform” rating and a $38.00 target price on the stock. William Blair reissued a “buy” rating on shares of Nektar Therapeutics in a report on Friday, June 14th. ValuEngine lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. Finally, BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. Nektar Therapeutics has an average rating of “Buy” and an average price target of $68.50.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
See Also: Cash Flow
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.